nav-left cat-right
cat-right

Software Mines Science Papers

Software that read tens of thousands of research papers and then predicted new discoveries about the workings of a protein that’s key to cancer could herald a faster approach to developing new drugs. The software, developed in a collaboration between IBM and Baylor College of Medicine, was set loose on more than 60,000 research papers that focused on p53, a protein involved in cell growth, which is implicated in most...

Online resources supporting drug discovery

Abstract Online resources enabling and supporting drug discovery have blossomed during the past ten years. However, drug hunters commonly find themselves overwhelmed by the proliferation of these computer-based resources. Ten years ago, we, the authors of this review, felt that a comprehensive list of in silico resources relating to drug discovery was needed. Especially because the internet provides a wealth of inspiring...

Biodatomics’ Open Source Approach

Maxim Mikheev is a co-founder and CEO of Biodatomics, gene informatics software companies. Mikheev is a molecular biologist, computer programmer, and aggressive entrepreneur. More uniquely, he is also an active member of the open source community, and BioDT, the platform his company unveiled two weeks ago at the ASHG conference in Boston, is open source from top to bottom. None of the roughly 400 distinct tools included in...

UC Santa Cruz Wins DREAM Breast Cancer Challenge

November 8, 2013 | A team of bioinformatics experts at UC Santa Cruz made the most accurate predictions in a competitive challenge to identify signaling networks in breast cancer cells. The results of the HPN-DREAM breast cancer network inference challenge were announced today in Toronto. The breast cancer network inference challenge was organized by the DREAM project (Dialogue on Reverse Engineering Assessment and Methods),...

PROTEROS ANNOUNCES APPOINTMENT OF NEW CHIEF FINANC...

Martinsried, Germany, October 11, 2012. Proteros biostructures GmbH (“Proteros”) today announced the appointment of Mr. Arnd Christ as Chief Financial Officer (CFO) as of 16th of November. Arnd Christ has more than 12 years of international experience as a CFO in the biotechnology industry, with responsibilities in finance, operations, legal affairs and investor relations. He has successfully conducted a number of...

Lonza, Avalanche Partner on Baculovirus-Based AAV ...

Biologics manufacturer Lonza and ocular gene therapy specialist Avalanche Biotechnologies established a global manufacturing collaboration to aid in the latter’s gene therapy programs. Avalanche’s lead wet age-related macular degeneration (wet-AMD) gene therapy candidate AVA-101 started in early clinical trials at the end of 2011. The partnership will focus on the process development and scale-up of a...
Page 3 of 912345...Last »